Consolidated Financial Highlights

26F

First Quarter

July 31st, 2026

Code:6737, TSE Prime Market

EIZO Corporation

Disclaimer Regarding Forward-looking Statements

Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of EIZO and its group companies, which are based on management's assumptions and beliefs in light of information currently available, and involve apparent or potential risks and uncertainties including forex impact, and risks related to supply and demand. Actual results may differ materially from these forecasts.

Note:"26Q1" appearing in this presentation means "First Quarter Fiscal year 2026".

"26F" appearing in this presentation means "Fiscal year 2026", that is Fiscal year ended March 31, 2027.

Details of the Market Group

Market Group	Market / Use
Business & Plus (B&P)	Financial institutions , Public authorities , Educational facilities , CAD , Commercial facilities , Business and home use
Healthcare (HC)	Diagnosis / Medical examination , Medical treatment / Operation , Healthcare-IT
Creative Work (CW)	Media & Entertainment , 3D computer graphics , Photo editing , Illustration , Design , Publication / Printing
Vertical & Specific (V&S)	For various mission critical environments, infrastructure and industrial equipment Air traffic control (ATC) , Maritime , Security & Surveillance (S&S) , Defense , Other industrial fields (including touch panel applications)
Amusement (AMU)	LCD-mounted pachinko and slot machines
Other (OTH)	Maintenance services and commissioned development of software

Contents

26Q1 Consolidated Summary

Sales and Profit Increased
Led by Overseas Performance & Favorable Exchange Rates

- **Net Sales: JPY 20.0 billion** (up JPY 2.7 billion YoY)
  - Although the European economy, a key region, remained subdued, B&P sales increased due to sales projects.
  - Sales for the HC and V&S markets remained strong overseas.
- **Operating Profit: JPY 0.8 billion** (up JPY 0.9 billion YoY)
  - Increase in Gross Profit: Driven by the increase in Net Sales and the favorable foreign exchange impact from the weaker yen against the euro.
  - Increase in SG&A Expenses: JPY 6.1 billion (up JPY 0.2 billion YoY)
    Decreased through fixed cost management resulting from the streamlining of operations in Europe, as well as the absence of one-time expenses related to the New Technology Hub recorded in the previous fiscal year. On the other hand, SG&A expenses increased due to FOREX effects when converting overseas group companies' SG&A expenses into JPY.
- **Net Income: JPY 1.2 billion** (up JPY 0.9 billion YoY)

Consolidated Income Statement

(JPY Million)

	25Q1	26Q1	YoY
Net Sales	17,338	20,031	115.5%
Gross Profit	5,839	6,937	118.8%
Gross Profit / Net Sales	33.7%	34.6%	1.0pt
Selling, General and Administrative Expenses	5,937	6,130	103.2%
Operating Profit	(97)	807	-
Operating Profit / Net Sales	(0.6%)	4.0%	4.6pt
Ordinary Profit	687	1,574	229.0%
Profit Attributable to Owners of Parent	307	1,215	394.7%

Exchange Rate(Quarterly Ave.): USD	JPY144.59	JPY159.57	JPY14.98
Exchange Rate(Quarterly Ave.): EUR	JPY163.81	JPY185.41	JPY21.60

Net Sales Drivers



- **B&P:** Although the economic environment in Europe has not improved, sales exceeded the same period of the previous fiscal year due to the steady accumulation of sales projects.
- **Healthcare:** For Diagnostics and Endoscopy, sales showed signs of recovery in Europe and North America, while sales expansion continued in India and the Middle East.
  In Japan, sales remained subdued due to the deterioration of the operating environment for hospitals.
- **Creative Work:** Sales remained subdued in Europe and North America.
- **V&S:** For Air Traffic Control applications, sales exceeded the same period of the previous fiscal year, as sales remained strong in Europe and China, and shipments for large-scale projects commenced in North America.
  Sales of monitors for Defense applications expanded in Europe and Japan.
- **Amusement:** Despite continued challenging market environment, sales increased year on year, driven by new models.
- **Other:** Sales of contract software development services for Amusement decreased.

Operating Income Drivers



- **FOREX:** Due to the depreciation of the JPY against the EUR
- **GPM:** Remained at a comparable level to the same period of the previous fiscal year, excluding FOREX.
- **SG&A Expenses:** Decreased through fixed cost management resulting from the restructuring and streamlining of the organization in Europe, as well as the absence of one-time expenses related to the New Technology Hub recorded in the same period of the previous fiscal year.

Net Sales: Overall



Overall Sales Development
(by Market)



Net Sales By Region
(B&P / HC / CW / V&S)

(JPY Billion)



Net Sales： B&P (Business & Plus)



- Although the economic environment in Europe has not improved, sales exceeded the same period of the previous fiscal year due to the steady accumulation of sales projects.
- In Japan, Net Sales were supported by contributions from large-scale projects.

Net Sales：Healthcare



Diagnostics

- Sales showed signs of recovery in Europe and North America, while sales expansion continued in India and the Middle East. In Japan, sales remained subdued as demand for capital investment continued to decline due to the deterioration of the operating environment for medical institutions.

OR Integration

- Sales remained strong both overseas and in Japan.

Endoscopy

- Sales showed signs of recovery in Europe and North America.

CuratOR® EX3245H

Net Sales： Creative Work



- Sales remained subdued in Europe and North America.
- In Japan, sales remained strong.

Net Sales : V&S (Vertical & Specific)



Air Traffic Control

- Net Sales exceeded the same period of the previous fiscal year, as sales remained strong in Europe and China, and shipments for large-scale projects commenced in North America.

Maritime

- Although demand for new shipbuilding remained high, Net Sales decreased comparably from the same period of the previous fiscal year due to the timing of deliveries.

DuraVision® FDX1502T-A

Security & Surveillance

- Net Sales exceeded the same period of the previous fiscal year, driven by sales in Japan.

Defense

- Sales of GPGPU(*) boards were strong in North America.
- In addition, sales of ruggedized monitors expanded in Europe and Japan.

(*) GPGPU (General-Purpose computing on Graphics Processing Units): Dedicated computing board for high-speed processing of large-scale calculations.

Net Sales：Amusement



- The market environment continues to be challenging, as the overall industry is shrinking due to a decline in the number of players and a reduction in the number of halls.

- Sales of new models increased.

©SANYO BUSSAN CO.,LTD.

Consolidated Balance Sheet

(JPY Million)

	25F	26Q1	Growth
Current Assets	84,776	81,755	(3,020)
Cash & Equivalents	20,352	23,598	3,245
Accounts Receivable etc.*	22,380	18,723	(3,656)
Inventories	37,742	37,434	(308)
Tangible Assets	26,321	26,204	(117)
Intangible Assets	836	742	(94)
Investments and Other Assets	65,547	158,451	92,903
Total	177,482	267,153	89,670
Current Liabilities	21,349	18,982	(2,367)
Short-term loans payable	5,502	5,560	58
Long term Liabilities	19,201	48,315	29,114
Shareholders' Equity	136,930	199,854	62,923
Total	177,482	267,153	89,670

The rise in market value of held shares increased Investment Securities, Deferred Tax Liabilities, and Valuation Difference on Available-for-Sale Securities.

* Notes and accounts receivable, contract assets and trade notes receivable transferred by endorsement

Contents

26F Business Strategy

(JPY Million)

	25F	26F Plan	25F vs.26F Plan
Net Sales	81,308	85,000	104.5%
Gross Profit	25,901	27,700	106.9%
Gross Profit / Net Sales	31.9%	32.6%	0.7pt
Selling, General and Administrative Expenses	23,535	24,400	103.7%
Operating Profit	2,365	3,300	139.5%
Operating Profit / Net Sales	2.9%	3.9%	1.0pt
Ordinary Profit	3,772	4,600	121.9%
Profit Attributable to Owners of Parent	7,323	6,500	88.8%
Exchange Rate(Yearly Ave.) :USD	JPY150.67	JPY160.00	JPY9.33
Exchange Rate(Yearly Ave.) :EUR	JPY174.64	JPY175.00	JPY0.36
ROA	2.3%	-	
ROE	5.6%	-	

No revision of 26F projected results announced on May 12, 2026.

Foreign Exchange Sensitivity

(Impact on Operating Income per JPY1 depreciation)

- USD: JPY 80 million (Negative)
- EUR: JPY 100 million (Positive)

Topic 1

Launched EIZO's First Dedicated Digital Pathology Monitor, Supporting the Global Shift Toward Digital Diagnosis.

- PX3150
  - 30.5" DCI 4K High-Precision Medical Monitor
- Accurate Color Reproduction for Pathology Diagnosis
  - Individually Calibrated for Trust from First Use
  - Color Accuracy Verification & Quality Control
  - Quality Control with Built-In Sensor
- Compliance with Global Standards for Pathology Use
  - FDA (USA) – Digital Pathology Display
  - IVDR (Europe) – Class A

PX3150

Topic 2

Introduced the World’s First 7-Year Manufacturer’s Warranty

Launched the World’s First 7-Year Manufacturer’s warranty for monitors, advancing sustainability through longer product lifecycles while delivering enhanced customer value and strengthening product differentiation.

The Foundations Supporting EIZO’s 7-Year Warranty

- Set rigorous testing and evaluation criteria during development, launching only products capable of maintaining stable long-term performance.
- Continuously improve products by incorporating insights gained from our global repair and support operations.
- In 2003, EIZO pioneered the industry's first "5-year standard warranty." Analysis of operational data accumulated over the years confirmed the long-term quality and reliability of our products.

EIZO Manufacturer’s Warranty
https://www.eizoglobal.com/support/warranty/

Topic 3

Kobe City Medical Center General Hospital: EIZO Reliability Supporting Mission-Critical Healthcare

Over 1,800 EIZO FlexScan EV2460 and EV2130 Monitors Deliver Reliable Visual Performance for Long-Term Healthcare Operations

Durability, Visibility, & Usability Required in Acute Care Healthcare

- High durability
  (ZERO failures from previous EIZO installations)
- Improved screen visibility
- Ergonomic design to reduce user fatigue
- Enhanced usability through expanded input terminals
- Flexible customization enabled by domestic production, including stand modifications

FlexScan EV2460 / EV2130



Share Buyback Authorization Increased to 5.5 Million Shares

- Flexibly utilize Share Buybacks as an important means of controlling the Company's capital structure
- Improve capital efficiency and enhance Total Shareholder Return (TSR)
- Fund Share Buybacks with cash on hand and investment securities
- Present a capital allocation roadmap with the next Mid-Term Business Plan (Scheduled for release within 2026)
- Actively promote growth investments, including M&A, utilizing investment securities
- Achieve sustainable ROE improvement and corporate value creation through profit growth and improved capital efficiency

	Before Amendments (Board of Directors Resolution dated May 12, 2026)	**After Amendments** (Board of Directors Resolution dated July 31, 2026)
(1) Type of shares to be acquired	Common shares of the Company	Common shares of the Company
(2) Total number of shares that may be acquired	1.5 million shares (max.) (3.79% of total number of issued shares excluding treasury shares)	5.5 million shares (max.) (13.91% of total number of issued shares excluding treasury shares)
(3) Total acquisition cost	JPY 4.0 billion (max.)	JPY 17.0 billion (max.)
(4) Acquisition period	May 25, 2026 to April 30, 2027	May 25, 2026 to May 24, 2027
(5) Method of acquisition	Market purchases on the Tokyo Stock Exchange	Market purchases on the Tokyo Stock Exchange (Including off-auction own share repurchase transactions through ToSTNeT-3)

Contents

Net Sales: B&P / Healthcare

(JPY Billion)

B&P



	23Q1	23Q2	23Q3	23Q4	24Q1	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1
Total	3.0	3.5	4.1	4.6	3.3	3.8	4.2	4.2	2.9	3.2	3.8	4.2	3.3
Overseas	2.0	2.5	3.0	2.9	2.4	2.7	3.0	2.4	1.9	2.2	2.7	2.3	2.2
Japan	0.9	1.0	1.0	1.6	0.9	1.0	1.2	1.8	0.9	1.0	1.1	1.8	1.0

Healthcare



	23Q1	23Q2	23Q3	23Q4	24Q1	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1
Total	8.2	8.8	9.1	10.4	7.7	7.6	8.4	10.1	7.4	8.6	9.2	11.2	8.4
Overseas	6.1	6.1	6.2	6.3	5.5	5.3	5.7	6.1	5.5	6.1	6.5	7.4	6.4
Japan	2.1	2.7	2.8	4.1	2.2	2.3	2.7	3.9	1.9	2.4	2.7	3.7	1.9

Net Sales: Creative Work / V&S

(JPY Billion)

Creative Work



	23Q1	23Q2	23Q3	23Q4	24Q1	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1
Total	1.4	1.2	1.7	1.4	1.2	1.2	1.7	1.2	1.1	1.2	1.6	1.2	1.0
Overseas	1.1	1.0	1.5	1.1	1.0	1.0	1.4	0.9	0.9	1.0	1.3	0.9	0.8
Japan	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.3	0.2

V&S

	23Q1	23Q2	23Q3	23Q4	24Q1	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1
Total	1.9	2.2	2.8	2.9	2.6	3.0	3.3	3.5	2.6	2.7	3.6	3.5	3.5
Overseas	1.0	1.1	1.6	1.9	1.7	2.1	2.1	2.4	1.7	1.6	2.2	2.2	2.3
Japan	0.8	1.0	1.2	1.0	0.8	0.9	1.1	1.0	0.8	1.1	1.3	1.3	1.2

Net Sales: Amusement / Other

(JPY Billion)

Amusement



	23Q1	23Q2	23Q3	23Q4	24Q1	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1
AMU	2.6	1.4	1.5	1.0	1.6	1.4	1.6	1.2	1.3	2.8	0.7	0.5	2.1

Other

	23Q1	23Q2	23Q3	23Q4	24Q1	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1
OTH	1.1	1.3	1.4	1.7	1.4	1.2	1.8	1.8	1.8	1.7	1.7	1.6	1.5

Selling, General and Administrative Expenses

(JPY Billion)



	23Q1	23Q2	23Q3	23Q4	24Q1	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1
TOTAL	5.2	5.3	5.5	5.3	5.7	5.3	5.8	5.4	5.9	5.7	6.0	5.7	6.1
Other	1.7	1.8	1.8	1.7	1.9	1.6	2.0	1.7	2.1	1.9	2.0	1.8	2.0
R&D	1.3	1.4	1.4	1.5	1.5	1.6	1.6	1.4	1.5	1.5	1.6	1.6	1.6
Personnel	2.0	2.1	2.1	2.0	2.2	2.1	2.2	2.2	2.2	2.1	2.3	2.2	2.4
SG&A / Net Sales	28.5%	28.8%	26.2%	24.0%	31.8%	28.7%	27.6%	24.4%	34.2%	28.0%	29.1%	25.6%	30.6%

Visit us online

www.eizoglobal.com